Allergen desensitization method
AssigneesDBV Technologies, Assistance Publique-Hopitaux de Paris, Université Paris Cité
InventorsChristophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
Life of this patent
Estimating the term…
Abstract
The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.
Claims18
A method for epicutaneous desensitization of a subject allergic to egg, the method comprising:
- a) epicutaneously exposing the subject to an egg allergen, without an adjuvant, and generating an immune reaction in the subject by applying a dose of the egg allergen, without an adjuvant, onto an intact region of skin of the subject;
- and
- b) repeatedly applying the egg allergen, without an adjuvant, to an intact region of the skin of the subject, at a dose, frequency or for an application time adapted to sustain the immune reaction, the exposure and sustained reaction leading to desensitization of the subject;
- wherein the egg allergen is applied, without an adjuvant, by a cutaneous occlusive device configured to ensure contact between the allergen and the region of skin, and wherein said dose of egg allergen is comprised between 0.1 and 1,000 μg/cm2 of a surface area of the device.
A method for epicutaneous desensitization of a subject allergic to egg, the method comprising:
- a) epicutaneously exposing the subject to an egg allergen, without an adjuvant, and generating an immune reaction in the subject by applying a dose of the egg allergen without an adjuvant, onto an intact region of skin of the subject, wherein:
- i) the egg allergen is applied, without an adjuvant, by a first cutaneous occlusive device,
- ii) the first cutaneous occlusive device is configured to ensure contact between the allergen and the region of skin, and
- iii) said dose of egg allergen is comprised between 0.1 and 1,000 μg/cm2 of a surface area of the first cutaneous occlusive device;
- b) removing the first cutaneous occlusive device at an amount of time after application of the first cutaneous occlusive device, and
- c) applying the same or different dose of the egg allergen, without an adjuvant, onto the same or different intact region of skin of the subject to sustain the immune reaction in the subject, wherein:
- i) the same or different dose of the egg allergen is applied, without an adjuvant, by an additional cutaneous occlusive device;
- ii) the additional cutaneous occlusive device is configured to ensure contact between the allergen and the region of skin, without an adjuvant, and
- iii) said same or different dose of egg allergen is comprised between 0.1 and 1,000 μg/cm2 of a surface area of the additional cutaneous occlusive device;
- d) optionally repeating steps b) and c) at least one additional time;
- and
- e) optionally, wherein the amount of time after which the first cutaneous occlusive device is removed is about 6 to 72 hours.
Dependencies are inferred from the claim text.